SEC Company Response from Adicet Bio, Inc. (ACET) (CIK 0001720580) (ACET) — Mar 19, 2026
Adicet Bio, Inc. (ACET) (CIK 0001720580)
Date: March 19, 2026 · CIK: 0001720580 · Accession: 0001720580-26-000017
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-294265
Letter
Adicet Bio, Inc.
131 Dartmouth Street, 3rd Floor
Boston, Massachusetts 02116
March 19, 2026
Via EDGAR Transmission
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Re: Adicet Bio, Inc.: Registration Statement on Form S-3, filed March 12, 2026 (File No. 333-294265), as amended
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Adicet Bio, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement, as amended (the “Registration Statement”) be accelerated to March 23, 2026, at 4:01 p.m. Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
Once the Registration Statement is effective, please orally confirm the event with Goodwin Procter LLP by calling Gabriela Morales-Rivera at (617) 570-1329. If you have any questions regarding this request, please contact Gabriela Morales-Rivera.
Sincerely,
Adicet Bio, Inc.
Show Raw Text
CORRESP
1
filename1.htm
CORRESP
Adicet Bio, Inc.
131 Dartmouth Street, 3rd Floor
Boston, Massachusetts 02116
March 19, 2026
Via EDGAR Transmission
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Re: Adicet Bio, Inc.: Registration Statement on Form S-3, filed March 12, 2026 (File No. 333-294265), as amended
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Adicet Bio, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement, as amended (the “Registration Statement”) be accelerated to March 23, 2026, at 4:01 p.m. Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
Once the Registration Statement is effective, please orally confirm the event with Goodwin Procter LLP by calling Gabriela Morales-Rivera at (617) 570-1329. If you have any questions regarding this request, please contact Gabriela Morales-Rivera.
Sincerely,
Adicet Bio, Inc.
/s/ Chen Schor
Chen Schor
President and Chief Executive Officer
cc: Nick Harvey, Chief Financial Officer, Adicet Bio, Inc.
Danielle Lauzon, Esq., Goodwin Procter LLP
Gabriela Morales-Rivera, Esq., Goodwin Procter LLP